156 related articles for article (PubMed ID: 35093003)
1. Impact of neoadjuvant intensity-modulated radiation therapy on borderline resectable pancreatic cancer with arterial abutment; a prospective, open-label, phase II study in a single institution.
Masui T; Nagai K; Anazawa T; Sato A; Uchida Y; Nakano K; Yogo A; Kaneda A; Nakamura N; Yoshimura M; Mizowaki T; Uza N; Fukuda A; Matsumoto S; Kanai M; Isoda H; Mizumoto M; Seo S; Hata K; Taura K; Kawaguchi Y; Takaori K; Uemoto S; Hatano E
BMC Cancer; 2022 Jan; 22(1):119. PubMed ID: 35093003
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of neoadjuvant chemoradiotherapy with moderately hypofractionated intensity-modulated radiotherapy for resectable pancreatic cancer: A prospective, open-label, phase II study.
Masui T; Nagai K; Anazawa T; Kasai Y; Yogo A; Yoshimura M; Mizowaki T; Uza N; Fukuda A; Matsumoto S; Kanai M; Isoda H; Kawaguchi Y; Uemoto S; Hatano E
Cancer Med; 2023 Sep; 12(18):18611-18621. PubMed ID: 37649318
[TBL] [Abstract][Full Text] [Related]
3. A Prospective Study of Intensity-modified Radiation Therapy in Comparison with Conventional 3D-RT for BR Pancreatic Cancer Patients with Arterial Involvement.
Masui T; Takaori K; Anazawa T; Sato A; Nakano K; Uchida Y; Yogo A; Goto Y; Matsumoto S; Kodama Y; Kanai M; Isoda H; Mizumoto M; Kawaguchi Y; Shibuya K; Itasaka S; Uemoto S
Anticancer Res; 2017 Dec; 37(12):7023-7030. PubMed ID: 29187490
[TBL] [Abstract][Full Text] [Related]
4. Oncological Benefits of Neoadjuvant Chemoradiation With Gemcitabine Versus Upfront Surgery in Patients With Borderline Resectable Pancreatic Cancer: A Prospective, Randomized, Open-label, Multicenter Phase 2/3 Trial.
Jang JY; Han Y; Lee H; Kim SW; Kwon W; Lee KH; Oh DY; Chie EK; Lee JM; Heo JS; Park JO; Lim DH; Kim SH; Park SJ; Lee WJ; Koh YH; Park JS; Yoon DS; Lee IJ; Choi SH
Ann Surg; 2018 Aug; 268(2):215-222. PubMed ID: 29462005
[TBL] [Abstract][Full Text] [Related]
5. A phase II trial of neoadjuvant chemoradiotherapy with intensity-modulated radiotherapy combined with gemcitabine and S-1 for borderline-resectable pancreatic cancer with arterial involvement.
Nagakawa Y; Hosokawa Y; Nakayama H; Sahara Y; Takishita C; Nakajima T; Hijikata Y; Kasuya K; Katsumata K; Tokuuye K; Tsuchida A
Cancer Chemother Pharmacol; 2017 May; 79(5):951-957. PubMed ID: 28378027
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant S-1 with concurrent radiotherapy followed by surgery for borderline resectable pancreatic cancer: study protocol for an open-label, multicentre, prospective phase II trial (JASPAC05).
Takahashi S; Ohno I; Ikeda M; Kobayashi T; Akimoto T; Kojima M; Konishi M; Uesaka K
BMJ Open; 2017 Oct; 7(10):e018445. PubMed ID: 29061632
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant Gemcitabine Chemotherapy followed by Concurrent IMRT Simultaneous Boost Achieves High R0 Resection in Borderline Resectable Pancreatic Cancer Patients.
Huang X; Knoble JL; Zeng M; Aguila FN; Patel T; Chambers LW; Hu H; Liu H
PLoS One; 2016; 11(12):e0166606. PubMed ID: 27935952
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant S-1 With Concurrent Radiotherapy Followed by Surgery for Borderline Resectable Pancreatic Cancer: A Phase II Open-label Multicenter Prospective Trial (JASPAC05).
Takahashi S; Ohno I; Ikeda M; Konishi M; Kobayashi T; Akimoto T; Kojima M; Morinaga S; Toyama H; Shimizu Y; Miyamoto A; Tomikawa M; Takakura N; Takayama W; Hirano S; Otsubo T; Nagino M; Kimura W; Sugimachi K; Uesaka K
Ann Surg; 2022 Nov; 276(5):e510-e517. PubMed ID: 33065644
[TBL] [Abstract][Full Text] [Related]
9. Relationship between surgical R0 resectability and findings of peripancreatic vascular invasion on CT imaging after neoadjuvant S-1 and concurrent radiotherapy in patients with borderline resectable pancreatic cancer.
Yasuta S; Kobayashi T; Aizawa H; Takahashi S; Ikeda M; Konishi M; Kojima M; Kuno H; Uesaka K; Morinaga S; Miyamoto A; Toyama H; Takakura N; Sugimachi K; Takayama W
BMC Cancer; 2020 Dec; 20(1):1184. PubMed ID: 33267820
[TBL] [Abstract][Full Text] [Related]
10. Borderline resectable pancreatic cancer: rationale for multidisciplinary treatment.
Takahashi S; Kinoshita T; Konishi M; Gotohda N; Kato Y; Kinoshita T; Kobayashi T; Mitsunaga S; Nakachi K; Ikeda M
J Hepatobiliary Pancreat Sci; 2011 Jul; 18(4):567-74. PubMed ID: 21331805
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant chemoradiation is associated with decreased lymph node ratio in borderline resectable pancreatic cancer: A propensity score matched analysis.
Peng JS; Morris-Stiff G; Ali NS; Wey J; Chalikonda S; El-Hayek KM; Walsh RM
Hepatobiliary Pancreat Dis Int; 2021 Feb; 20(1):74-79. PubMed ID: 32861576
[TBL] [Abstract][Full Text] [Related]
12. Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma.
Mellon EA; Hoffe SE; Springett GM; Frakes JM; Strom TJ; Hodul PJ; Malafa MP; Chuong MD; Shridhar R
Acta Oncol; 2015 Jul; 54(7):979-85. PubMed ID: 25734581
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant therapy for pancreatic cancer: an intention-to-treat analysis.
Okada K; Murakami Y; Uemura K; Kondo N; Nakagawa N; Seo S; Otsuka H; Takahashi S
Langenbecks Arch Surg; 2020 Aug; 405(5):623-633. PubMed ID: 32592044
[TBL] [Abstract][Full Text] [Related]
14. Perioperative outcomes and survival following neoadjuvant stereotactic body radiation therapy (SBRT) versus intensity-modulated radiation therapy (IMRT) in pancreatic adenocarcinoma.
Chapman BC; Gleisner A; Rigg D; Meguid C; Goodman K; Brauer B; Gajdos C; Schulick RD; Edil BH; McCarter MD
J Surg Oncol; 2018 Apr; 117(5):1073-1083. PubMed ID: 29448308
[TBL] [Abstract][Full Text] [Related]
15. Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer: Alliance for Clinical Trials in Oncology Trial A021101.
Katz MH; Shi Q; Ahmad SA; Herman JM; Marsh Rde W; Collisson E; Schwartz L; Frankel W; Martin R; Conway W; Truty M; Kindler H; Lowy AM; Bekaii-Saab T; Philip P; Talamonti M; Cardin D; LoConte N; Shen P; Hoffman JP; Venook AP
JAMA Surg; 2016 Aug; 151(8):e161137. PubMed ID: 27275632
[TBL] [Abstract][Full Text] [Related]
16. Treatment Strategy for Borderline Resectable Pancreatic Cancer With Radiographic Artery Involvement.
Hirono S; Kawai M; Okada KI; Miyazawa M; Shimizu A; Kitahata Y; Ueno M; Yamaue H
Pancreas; 2016 Nov; 45(10):1438-1446. PubMed ID: 27088490
[TBL] [Abstract][Full Text] [Related]
17. Outcomes of neoadjuvant gemcitabine plus S-1 and radiation therapy for borderline resectable pancreatic cancer.
Yabushita Y; Matsuyama R; Miyake K; Homma Y; Kumamoto T; Misumi T; Hata M; Yamanaka S; Fujii S; Endo I
J Hepatobiliary Pancreat Sci; 2023 Apr; 30(4):493-502. PubMed ID: 36178433
[TBL] [Abstract][Full Text] [Related]
18. A Prospective Multicenter Phase II Trial of Neoadjuvant Chemotherapy with Gemcitabine Plus Nab-Paclitaxel for Borderline Resectable Pancreatic Cancer with Arterial Involvement.
Ikenaga N; Miyasaka Y; Ohtsuka T; Nakata K; Adachi T; Eguchi S; Nishihara K; Inomata M; Kurahara H; Hisaka T; Baba H; Nagano H; Ueki T; Noshiro H; Tokunaga S; Ishigami K; Nakamura M;
Ann Surg Oncol; 2023 Jan; 30(1):193-202. PubMed ID: 36207481
[TBL] [Abstract][Full Text] [Related]
19. A Prospective Phase II Trial of Neoadjuvant S-1 with Concurrent Hypofractionated Radiotherapy in Patients with Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma.
Okano K; Suto H; Oshima M; Maeda E; Yamamoto N; Kakinoki K; Kamada H; Masaki T; Takahashi S; Shibata T; Suzuki Y
Ann Surg Oncol; 2017 Sep; 24(9):2777-2784. PubMed ID: 28608121
[TBL] [Abstract][Full Text] [Related]
20. Meta-analysis comparing upfront surgery with neoadjuvant treatment in patients with resectable or borderline resectable pancreatic cancer.
Versteijne E; Vogel JA; Besselink MG; Busch ORC; Wilmink JW; Daams JG; van Eijck CHJ; Groot Koerkamp B; Rasch CRN; van Tienhoven G;
Br J Surg; 2018 Jul; 105(8):946-958. PubMed ID: 29708592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]